CVOT summit report 2024: new cardiovascular, kidney, and metabolic outcomes

Oliver Schnell¹, Jaime Almandoz², Lisa Anderson^{3

4}, Katharine Barnard-Kelly⁵, Tadej Battelino^{6

7}, Matthias Blüher^{8

9}, Luca Busetto¹⁰, Doina Catrinou¹¹, Antonio Ceriello¹², Xavier Cos¹³, Thomas Danne¹⁴, Colin M Dayan¹⁵, Stefano Del Prato¹⁶, Beatriz Fernández-Fernández^{17

18}, Paola Fioretto¹⁹, Thomas Forst²⁰, James R Gavin²¹, Francesco Giorgino²², Per-Henrik Groop^{23

24

25

26}, Igor A Harsch²⁷, Hiddo J L Heerspink²⁸, Lutz Heinemann²⁹, Mahmoud Ibrahim³⁰, Michel Jadoul³¹, Sarah Jarvis³², Linong Ji³³, Naresh Kanumilli³⁴, Mikhail Kosiborod³⁵, Ulf Landmesser³⁶, Sofia Macieira³⁷, Boris Mankovsky³⁸, Nikolaus Marx³⁹, Chantal Mathieu⁴⁰, Barbara McGowan⁴¹, Tatjana Milenkovic^{42

43}, Othmar Moser^{44

45}, Dirk Müller-Wieland⁴⁶, Nikolaos Papanas⁴⁷, Dipesh C Patel⁴⁸, Andreas F H Pfeiffer^{49

50}, Dario Rahelić⁵¹, Helena W Rodbard⁵², Lars Rydén⁵³, Elke Schaeffner⁵⁴, C Wendy Spearman⁵⁵, Alin Stirban⁵⁶, Frank Tacke⁵⁷, Pinar Topsever⁵⁸, Luc Van Gaal⁵⁹, Eberhard Standl⁶⁰

Affiliations

¹ Forschergruppe Diabetes e. V., Helmholtz Center Munich, Ingolstaedter Landstraße 1, 85764, Neuherberg (Munich), Germany. oliver.schnell@lrz.uni-muenchen.de.
² Division of Endocrinology, Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX, USA.
³ Molecular and Clinical Sciences Research Institute, St. George's University of London, London, UK.
⁴ St. George's University Hospitals NHS Foundation Trust, London, UK.
⁵ Southern Health NHS Foundation Trust, Southampton, UK.
⁶ University Medical Center, Ljubljana, Slovenia.
⁷ Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia.
⁸ Helmholtz Institute for Metabolic, Obesity and Vascular Research (HI-MAG) of the Helmholtz Zentrum München at the University of Leipzig and University Hospital Leipzig, Leipzig, Germany.
⁹ Medical Department III-Endocrinology, Nephrology, Rheumatology, University of Leipzig Medical Center, Leipzig, Germany.
¹⁰ Department of Medicine (DIMED), University of Padova, Padua, Italy.
¹¹ Faculty of Medicine, Ovidius University of Constanta, Constanta, Romania.
¹² IRCCS MultiMedica, Milan, Italy.
¹³ DAP Cat Research Group, Foundation University Institute for Primary Health Care Research Jordi Gol i Gorina, Barcelona, Spain.
¹⁴ NOVA Medical School, Lisbon, Portugal.
¹⁵ Cardiff University School of Medicine, Cardiff, UK.
¹⁶ Interdisciplinary Research Center "Health Science", Sant'Anna School of Advanced Studies, Pisa, Italy.
¹⁷ Division of Nephrology and Hypertension, University Hospital Fundación Jiménez Díaz, Madrid, Spain.
¹⁸ Faculty of Medicine, Autonomous University of Madrid, Madrid, Spain.
¹⁹ Faculty of Medicine, University of Padova, Padua, Italy.
²⁰ CRS Clinical Research Services Mannheim GmbH, Mannheim, Germany.
²¹ Emory University School of Medicine, Atlanta, GA, USA.
²² Department of Precision and Regenerative Medicine and Ionian Area, University of Bari Aldo Moro, Bari, Italy.
²³ Department of Nephrology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.
²⁴ Folkhälsan Research Center, Biomedicum, Helsinki, Finland.
²⁵ Department of Diabetes, Central Medical School, Monash University, Melbourne, Australia.
²⁶ Baker Heart and Diabetes Institute, Melbourne, VIC, Australia.
²⁷ Division of Endocrinology and Metabolism, Department of Internal Medicine II, Thuringia Clinic Saalfeld "Georgius Agricola", Saalfeld, Germany.
²⁸ Department of Clinical Pharmacy and Pharmacology, University Medical Centre Groningen, University of Groningen, Groningen, The Netherlands.
²⁹ Science Consulting in Diabetes GmbH, Dusseldorf, Germany.
³⁰ EDC, Centre for Diabetes Education, Charlotte, USA.
³¹ Division of Nephrology, Cliniques Universitaires Saint-Luc, Université Catholique de Louvain, Brussels, Belgium.
³² General Practitioner, London, UK.
³³ Peking University People's Hospital, Xicheng District, Beijing, China.
³⁴ Manchester University Foundation Trust, Manchester, UK.
³⁵ Department of Cardiovascular Disease, Saint Luke's Mid America Heart Institute, University of Missouri-Kansas City School of Medicine, Kansas City, MO, USA.
³⁶ Department of Cardiology Angiology and Intensive Care Medicine, Charité Universitätsmedizin Berlin, Berlin, Germany.
³⁷ Sciarc GmbH, Baierbrunn, Germany.
³⁸ Depatment of Diabetology, Shupyk National Healthcare University of Ukraine, Kiev, Ukraine.
³⁹ Clinic for Cardiology, Pneumology, Angiology and Internal Intensive Care Medicine (Medical Clinic I), RWTH Aachen University Hospital, Aachen, Germany.
⁴⁰ Department of Endocrinology, Catholic University of Louvain, Louvain, Belgium.
⁴¹ Guy's and St Thomas' Hospital, Kings College London, London, UK.
⁴² University Clinic of Endocrinology, Diabetes and Metabolic Diseases, Skopje, North Macedonia.
⁴³ Faculty of Medicine "St. Cyril and Methodius" University, Skopje, North Macedonia.
⁴⁴ Institute of Sports Science, University of Bayreuth, Bayreuth, Germany.
⁴⁵ Interdisciplinary Metabolic Medicine Trials Unit, Division of Endocrinology and Diabetology, Medical University of Graz, Graz, Austria.
⁴⁶ Department of Medicine I, University Hospital Aachen, Aachen, Germany.
⁴⁷ Diabetes Centre-Diabetic Foot Clinic, Second Department of Internal Medicine, Democritus University of Thrace, Alexandroupolis, Greece.
⁴⁸ Royal Free London, University College London, London, UK.
⁴⁹ Department of Endocrinology and Metabolic Diseases, Charité Universitätsmedizin Berlin, Campus Benjamin Franklin, Berlin, Germany.
⁵⁰ Deutsches Zentrum für Diabetesforschung e.V., Helmholtz Center Munich, Neuherberg, Germany.
⁵¹ Vuk Vrhovac University Clinic for Diabetes, Endocrinology and Metabolic Diseases at Merkur University Hospital, Zagreb, Croatia.
⁵² Endocrine and Metabolic Consultants, Rockville, MD, USA.
⁵³ Department of Medicine K2, Karolinska Institute, Stockholm, Sweden.
⁵⁴ Institute of Public Health, Charité Universitätsmedizin Berlin, Berlin, Germany.
⁵⁵ Division of Hepatology, Department of Medicine, Faculty of Health Sciences, University of Cape Town, Cape Town, South Africa.
⁵⁶ Asklepios Klinik Birkenwerder, Birkenwerder, Germany.
⁵⁷ Department of Hepatology and Gastroenterology, Charité - Universitätsmedizin Berlin, Campus Virchow-Klinikum and Campus Charité Mitte, Berlin, Germany.
⁵⁸ Department of Family Medicine, Acıbadem Mehmet Ali Aydınlar University School of Medicine, Istanbul, Turkey.
⁵⁹ Department of Endocrinology-Diabetology and Metabolism, Antwerp University Hospital, Antwerp, Belgium.
⁶⁰ Forschergruppe Diabetes e. V., Helmholtz Center Munich, Ingolstaedter Landstraße 1, 85764, Neuherberg (Munich), Germany.

PMID: 40316962
PMCID: PMC12048985
DOI: 10.1186/s12933-025-02700-0

CVOT summit report 2024: new cardiovascular, kidney, and metabolic outcomes

Oliver Schnell et al. Cardiovasc Diabetol. 2025.

. 2025 May 2;24(1):187.

doi: 10.1186/s12933-025-02700-0.

Authors

Affiliations

¹ Forschergruppe Diabetes e. V., Helmholtz Center Munich, Ingolstaedter Landstraße 1, 85764, Neuherberg (Munich), Germany. oliver.schnell@lrz.uni-muenchen.de.
² Division of Endocrinology, Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX, USA.
³ Molecular and Clinical Sciences Research Institute, St. George's University of London, London, UK.
⁴ St. George's University Hospitals NHS Foundation Trust, London, UK.
⁵ Southern Health NHS Foundation Trust, Southampton, UK.
⁶ University Medical Center, Ljubljana, Slovenia.
⁷ Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia.
⁸ Helmholtz Institute for Metabolic, Obesity and Vascular Research (HI-MAG) of the Helmholtz Zentrum München at the University of Leipzig and University Hospital Leipzig, Leipzig, Germany.
⁹ Medical Department III-Endocrinology, Nephrology, Rheumatology, University of Leipzig Medical Center, Leipzig, Germany.
¹⁰ Department of Medicine (DIMED), University of Padova, Padua, Italy.
¹¹ Faculty of Medicine, Ovidius University of Constanta, Constanta, Romania.
¹² IRCCS MultiMedica, Milan, Italy.
¹³ DAP Cat Research Group, Foundation University Institute for Primary Health Care Research Jordi Gol i Gorina, Barcelona, Spain.
¹⁴ NOVA Medical School, Lisbon, Portugal.
¹⁵ Cardiff University School of Medicine, Cardiff, UK.
¹⁶ Interdisciplinary Research Center "Health Science", Sant'Anna School of Advanced Studies, Pisa, Italy.
¹⁷ Division of Nephrology and Hypertension, University Hospital Fundación Jiménez Díaz, Madrid, Spain.
¹⁸ Faculty of Medicine, Autonomous University of Madrid, Madrid, Spain.
¹⁹ Faculty of Medicine, University of Padova, Padua, Italy.
²⁰ CRS Clinical Research Services Mannheim GmbH, Mannheim, Germany.
²¹ Emory University School of Medicine, Atlanta, GA, USA.
²² Department of Precision and Regenerative Medicine and Ionian Area, University of Bari Aldo Moro, Bari, Italy.
²³ Department of Nephrology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.
²⁴ Folkhälsan Research Center, Biomedicum, Helsinki, Finland.
²⁵ Department of Diabetes, Central Medical School, Monash University, Melbourne, Australia.
²⁶ Baker Heart and Diabetes Institute, Melbourne, VIC, Australia.
²⁷ Division of Endocrinology and Metabolism, Department of Internal Medicine II, Thuringia Clinic Saalfeld "Georgius Agricola", Saalfeld, Germany.
²⁸ Department of Clinical Pharmacy and Pharmacology, University Medical Centre Groningen, University of Groningen, Groningen, The Netherlands.
²⁹ Science Consulting in Diabetes GmbH, Dusseldorf, Germany.
³⁰ EDC, Centre for Diabetes Education, Charlotte, USA.
³¹ Division of Nephrology, Cliniques Universitaires Saint-Luc, Université Catholique de Louvain, Brussels, Belgium.
³² General Practitioner, London, UK.
³³ Peking University People's Hospital, Xicheng District, Beijing, China.
³⁴ Manchester University Foundation Trust, Manchester, UK.
³⁵ Department of Cardiovascular Disease, Saint Luke's Mid America Heart Institute, University of Missouri-Kansas City School of Medicine, Kansas City, MO, USA.
³⁶ Department of Cardiology Angiology and Intensive Care Medicine, Charité Universitätsmedizin Berlin, Berlin, Germany.
³⁷ Sciarc GmbH, Baierbrunn, Germany.
³⁸ Depatment of Diabetology, Shupyk National Healthcare University of Ukraine, Kiev, Ukraine.
³⁹ Clinic for Cardiology, Pneumology, Angiology and Internal Intensive Care Medicine (Medical Clinic I), RWTH Aachen University Hospital, Aachen, Germany.
⁴⁰ Department of Endocrinology, Catholic University of Louvain, Louvain, Belgium.
⁴¹ Guy's and St Thomas' Hospital, Kings College London, London, UK.
⁴² University Clinic of Endocrinology, Diabetes and Metabolic Diseases, Skopje, North Macedonia.
⁴³ Faculty of Medicine "St. Cyril and Methodius" University, Skopje, North Macedonia.
⁴⁴ Institute of Sports Science, University of Bayreuth, Bayreuth, Germany.
⁴⁵ Interdisciplinary Metabolic Medicine Trials Unit, Division of Endocrinology and Diabetology, Medical University of Graz, Graz, Austria.
⁴⁶ Department of Medicine I, University Hospital Aachen, Aachen, Germany.
⁴⁷ Diabetes Centre-Diabetic Foot Clinic, Second Department of Internal Medicine, Democritus University of Thrace, Alexandroupolis, Greece.
⁴⁸ Royal Free London, University College London, London, UK.
⁴⁹ Department of Endocrinology and Metabolic Diseases, Charité Universitätsmedizin Berlin, Campus Benjamin Franklin, Berlin, Germany.
⁵⁰ Deutsches Zentrum für Diabetesforschung e.V., Helmholtz Center Munich, Neuherberg, Germany.
⁵¹ Vuk Vrhovac University Clinic for Diabetes, Endocrinology and Metabolic Diseases at Merkur University Hospital, Zagreb, Croatia.
⁵² Endocrine and Metabolic Consultants, Rockville, MD, USA.
⁵³ Department of Medicine K2, Karolinska Institute, Stockholm, Sweden.
⁵⁴ Institute of Public Health, Charité Universitätsmedizin Berlin, Berlin, Germany.
⁵⁵ Division of Hepatology, Department of Medicine, Faculty of Health Sciences, University of Cape Town, Cape Town, South Africa.
⁵⁶ Asklepios Klinik Birkenwerder, Birkenwerder, Germany.
⁵⁷ Department of Hepatology and Gastroenterology, Charité - Universitätsmedizin Berlin, Campus Virchow-Klinikum and Campus Charité Mitte, Berlin, Germany.
⁵⁸ Department of Family Medicine, Acıbadem Mehmet Ali Aydınlar University School of Medicine, Istanbul, Turkey.
⁵⁹ Department of Endocrinology-Diabetology and Metabolism, Antwerp University Hospital, Antwerp, Belgium.
⁶⁰ Forschergruppe Diabetes e. V., Helmholtz Center Munich, Ingolstaedter Landstraße 1, 85764, Neuherberg (Munich), Germany.

PMID: 40316962
PMCID: PMC12048985
DOI: 10.1186/s12933-025-02700-0

Abstract

The 10th Cardiovascular Outcome Trial (CVOT) Summit: Congress on Cardiovascular, Kidney, and Metabolic Outcomes was held virtually on December 5-6, 2024. This year, discussions about cardiovascular (CV) and kidney outcome trials centered on the recent findings from studies involving empagliflozin (EMPACT-MI), semaglutide (STEP-HFpEF-DM and FLOW), tirzepatide (SURMOUNT-OSA and SUMMIT), and finerenone (FINEARTS-HF). These studies represent significant advances in reducing the risk of major adverse cardiovascular events (MACE) and improving metabolic outcomes in heart failure with preserved ejection fraction (HFpEF), chronic kidney disease (CKD), and obstructive sleep apnea (OSA). The congress also comprised sessions on novel and established therapies for managing HFpEF, CKD, and obesity; guidelines for managing CKD and metabolic dysfunction-associated steatotic liver disease (MASLD); organ crosstalk and the development of cardio-kidney-metabolic (CKM) syndrome; precision medicine and person-centered management of diabetes, obesity, cardiovascular disease (CVD) and CKD; early detection of type 1 diabetes (T1D) and strategies to delay its onset; continuous glucose monitoring (CGM) and automated insulin delivery (AID); cardiovascular autonomic neuropathy (CAN) and the diabetic heart; and the role of primary care in the early detection, prevention and management of CKM diseases. The contribution of environmental plastic pollution to CVD risk, the increasing understanding of the efficacy and safety of incretin therapies in the treatment of CKM diseases, and the latest updates on nutrition strategies for CKM management under incretin-based therapies were also topics of interest for a vast audience of endocrinologists, diabetologists, cardiologists, nephrologists and primary care physicians, who actively engaged in online discussions. The 11th CVOT Summit will be held virtually on November 20-21, 2025 ( http://www.cvot.org ).

Keywords: CGM; CKM; Cardiovascular disease; Chronic kidney disease; Diabetes; Finerenone; GLP-1 RA; Guidelines; Heart failure; MASLD; Obesity; SGLT2 inhibitor; Tirzepatide.

PubMed Disclaimer

Conflict of interest statement

Declarations. Ethics approval and consent to participate: Not applicable. Consent for publication: Not applicable. Competing interests: OS (Oliver Schnell) is the founder and CEO of Sciarc and reports consulting, speaking, or serving on advisory boards for AstraZeneca, Bayer, Boehringer Ingelheim, Lilly, MSD, Mundipharma, Novo Nordisk, Roche, Sanofi, and Wörwag Pharma. JA (Jaime Almandoz) declares that he has no competing interests. LA (Lisa Anderson) received speaker fees from Vifor, Alnylam, served on advisory boards for Alnylam, Pharmacosmos, received research support from Pfizer and travel and accommodation expenses from Abbott and Roche. KBK (Katharine Barnard-Kelly) is founder and shareholder at Spotlight-AQ Ltd. KBK has received research support from Dexcom, Embecta, JDRF, Novo Nordisk and Roche Diabetes Care, and honoraria from Sanofi. TB (Tadej Battelino) has served on the advisory boards of Abbott, Boehringer Ingelheim, Dreamed Diabetes, Eli Lilly and Company, Indigo Diabetes, Medtronic, Novo Nordisk, and Sanofi. TB has received speaker’s bureau honoraria from Abbott, Eli Lilly and Company, Medtronic, Novo Nordisk, Roche, and Sanofi. The University Medical Center has received research grant support from Abbott, GluSense, Medtronic, Novo Nordisk, Sandoz, Sanofi, and Zealand Pharma. MB (Matthias Blüher) received honoraria as a consultant and speaker from Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Daiichi-Sankyo, Lilly, Novo Nordisk, Novartis, and Sanofi. LB (Luca Busetto) declares that he has no competing interests. DC (Doina Catrinou) declares that she has no competing interests. AC (Antonio Ceriello) disclosed the following conflict of interest: Advisory Board, Consultancy, Lectures: Abbott, Bayer, Berlin Chemie, Boehringer Ingelheim, Hikamr Pharma, Guidotti, Eli Lilly, MSD, Merck, Novo, Roche Diagnostics, Sanofi, Servier, SUN Pharma. XC (Xavier Cos) declares that he has no competing interests. TD (Thomas Danne) declares that he has no competing interests. CMD (Colin M. Dayan) declares that he has no competing interests. SDP (Stefano Del Prato) served as president of the European Association for the Study of Diabetes (EASD)/European Foundation for the Study of Diabetes (EFSD) from 2020 to 2022; Is currently President of Fondazione Menarini; has served as an advisor for Abbott, Amarin Corporation, Amplitude, Applied Therapeutics, AstraZeneca, Biomea Fusion, Eli Lilly & Co., EvaPharma, Menarini International, Novo Nordisk, Sanofi, and Sun Pharmaceuticals; and has received fees for speaking from AstraZeneca, Berlin-Chemie, Boehringer Ingelheim, Eli Lilly & Co., Laboratori Guidotti, Menarini International, Novo Nordisk, and Sanofi. BFF (Beatriz Fernández-Fernández) has received grants from AstraZeneca and Esteve and consultancy or speaker fees or travel support from Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Eli Lilly and Company, Menarini, Novo Nordisk, and Mundipharma.TF (Thomas Forst) has been a member of the speaker panel of Amarin, AstraZeneca, Boehringer Ingelheim, Berlin-Chemie, Cipla, Daiichi-Sankyo, Eli Lilly and Company, Fortbildungskolleg, MSD, Novartis, Novo Nordisk, Sanofi, Santis, and of the advisory panel of Atrogi, Bayer, Cipla, Diabetes-Akademie Bad Mergentheim e.V., Eli Lilly and Company, Eyesense, Fortbildungskolleg, Novo Nordisk, Pfizer, reMYND, Roche and Sanofi. PF (Paola Fioretto) has received fees as consultant and speaker for AstraZeneca, Bayer, Boehringer Ingelheim, Eli Lilly company and Novo Nordisk. TF (Thomas Forst) is an employee of CRS Clinical Research Services GmbH, Germany and has contributed to speaker panels for Amarin, AstraZeneca, Boehringer Ingelheim, Berlin Chemie, Cipla, Daiichi-Sankyo, Eli Lilly and Company, Fortbildungskolleg, MSD, Novartis, Novo Nordisk, Sanofi, and Santis and advisory panels for AstraZeneca, Atrogi, Bayer, Cipla, Diabetes Akademie Bad Mergentheim, Eli Lilly and Company, Eysense, Fortbildungskolleg, Novo Nordisk, Pfizer, Sanofi, Remynd, and Roche. JRG (James R. Gavin III) has served on the advisory boards of Abbott Diabetes Care and Embecta, and on the speaker’s bureaus of Boehringer Ingelheim and Eli Lilly and Company. FG (Francesco Giorgino) has served on Advisory Boards: AstraZeneca, Biomea, Boehringer-Ingelheim, Eli Lilly, Medtronic, NovoNordisk, Roche Diabetes Care, Sanofi; Other Boards: Senior Vice-President of the European Association for the Study of Diabetes (EASD)/European Foundation for the Study of Diabetes (EFSD); Consultant: Eli Lilly, NovoNordisk, Biomea; Lectures, presentations, or educational events: AstraZeneca, Boehringer-Ingelheim, Eli Lilly, Lifescan, Merck Sharp & Dohme, Medtronic, NovoNordisk, Roche Diabetes Care, Sanofi; Research Support: Eli Lilly, Roche Diabetes Care; Receipt of Medical Writing or Support for Statistical Analysis: AstraZeneca, Eli Lilly, NovoNordisk, Roche Diabetes Care, Sanofi. PHG (Per-Henrik Groop) has received lecture honoraria from Astellas, AstraZeneca, Bayer, Boehringer Ingelheim, Berlin Chemie, Eli Lilly and Company, EloWater, Genzyme, Medscape, MSD, Mundipharma, Novartis, Novo Nordisk, Peer Voice, Sanofi and Sciarc. PHG also serves as an advisory board member for AbbVie, Astellas, AstraZeneca, Bayer, Boehringer Ingelheim, Eli Lilly and Company, Medscape, MSD, Mundipharma, Novartis, Novo Nordisk, and Sanofi. IAH (Igor A. Harsch) has received speaker and/or consultancy fees from Bristol Myers Squibb, Almirall, Boehringer Ingelheim, Lilly Deutschland GmbH, NOVO Nordisk, and AbbVie. HJLH (Hiddo J.L. Heerspink) declares that he has no competing interests. LH (Lutz Heinemann) declares that he has no competing interests. MI (Mahmoud Ibrahim) has consultancy agreement with and received speaker honoraria from Boehringer Ingelheim, Medtronic, Novo Nordisk, and Pfizer. MJ (Michel Jadoul) has received speaker and/or consultancy fees from Astellas, Astra-Zeneca, Bayer, Boehringer-Ingelheim,Cardiorenal, CSL Vifor, GSK, Novo Nordisk, Menarini, Stada-EG and Vertex. He is since januari 2019 cochair of Kidney Disease: Improving Global Outcomes (KDIGO). SJ (Sarah Jarvis) declares that she has no competing interests. LJ (Linong Ji) declares that he has no competing interests. NK (Naresh Kanumilli) declares that he has no competing interests. MK (Mikhail Kosiborod) reports consulting or advisory board participation for 35Pharma, Alnylam Pharmaceuticals, Amgen, Applied Therapeutics, AstraZeneca, Bayer, Boehringer Ingelheim, Cytokinetics, Dexcom, Eli Lilly and Company, Esperion Therapeutics, Janssen Pharmaceuticals, Lexicon Pharmaceuticals, Merck (Diabetes and Cardiovascular), Novo Nordisk, Pharmacosmos, Pfizer, scPharmaceuticals, Sanofi, Structure Therapeutics, Vifor Pharma and Youngene Therapeutics. MK has also received honoraria from AstraZeneca, Boehringer Ingelheim and Novo Nordisk, and research grants from AstraZeneca, Boehringer Ingelheim and Pfizer. UL (Ulf Landmesser) declares that he has no competing interests. SM (Sofia Macieira) is an employee of Sciarc. BM (Boris Mankovsky) has served on advisory boards and received speaking fees from AstraZeneca, Bayer, Boehringer Ingelheim, Novartis, Novo Nordisk, Sanofi, Servier, and Wörwag Pharma. NM (Nikolaus Marx) has received research grants from Boehringer Ingelheim and MSD, speaking fees form Amgen, AstraZeneca, Bayer, BMS, Boehringer Ingelheim, Eli Lilly and Company, MSD, Novo Nordisk, and Sanofi-Aventis and has served or serves on the advisory board of Amgen, Bayer, BMS, Boehringer Ingelheim, MSD, Novo Nordisk, and Sanofi-Aventis. CM (Chantal Mathieu) serves or has served on the advisory panel for ActoBio Therapeutics, Avotres, AstraZeneca, Boehringer Ingelheim, Eli Lilly and Company, Imcyse, Insulet, Mannkind, Medtronic, Merck Sharp and Dohme Ltd., Novartis, Novo Nordisk, Pfizer, Sandoz, Sanofi, Roche, Vertex and Zealand Pharma. CM serves or has served on the speakers’ bureau for AstraZeneca, Boehringer Ingelheim, Eli Lilly and Company, Novartis Novo Nordisk, and Sanofi. Financial compensation for these activities has been received by KU Leuven. KU Leuven has received research support for CM from ActoBio Therapeutics, Imcyse, Medtronic, Novo Nordisk, and Sanofi. BM (Barbara McGowan) has received grant/research supports and/or honoraria/consultation fees by Novo Nordisk, Lilly, Boehringer Ingelheim, and Astrazeneca. BM has received speaker’s bureau honoraria from Novo Nordisk, Lilly, and Amgen. TM (Tatjana Milenkovic) declares that she has no competing interests. OM (Othmar Moser) declares that he has no competing interests. DMW (Dirk Müller-Wieland) participates in advisory boards and has served on the speaker bureau for Amarin, Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Daiichi-Sankyo, GlaxoSmithKline, Novartis, Novo Nordisk, and Sanofi. NP (Nikolaos Papanas) declares that he has no competing interests. DCP (Dipesh C. Patel) has served on advisory panels for AstraZeneca, Boehringer Ingelheim, Eli Lilly, and Sanofi and was involved in educational work for Astra Zeneca, Eli Lilly, Novo Nordisk. AP (Andreas Pfeiffer) declares that he has no competing interests. DR (Dario Raheliċ) declares that he has no competing interests. HWR (Helena W. Rodbard) has served on advisory boards for Bayer, Dexcom, Endogenex, Kriya, and Pacira. She has received research support from Eli Lilly, Invesago, Medtronic, Novo Nordisk, and Sanofi. She has participated in Speakers Bureau for Eli Lilly. LR (Lars Rydén) declares that he has no competing interests. ES (Elke Schaeffner) has received honorarium from the National Kidney Foundation for international editorship for the American Journal of Kidney Diseases, from AstraZeneca for consulting and Amgen for session moderation. She was member of the KDIGO working group for the 2024 guideline on CKD evaluation and management. WS (Wendy Spearman) declares that she has no competing interests. AS (Alin Stirban) declares that he has no competing interests. FT (Frank Tacke) declares that work in his lab has been supported by research grants from AstraZeneca, Gilead, and MSD. F. T. has received honoraria for consulting or lectures from AstraZeneca, Gilead, AbbVie, BMS, Boehringer, Madrigal, Falk, MSD, GSK, Pfizer, Novo Nordisk, Sanofi, and Novartis. PT (Pinar Topsever) has received honoraria or consulting fees from AstraZeneca, Boehringer Ingelheim, Eli Lilly and Company, and LifeScan, and has served on the speaker’s bureau for AstraZeneca. PT received grant/research support from PCDE, made possible by corporate sponsorship from AstraZeneca, Eli Lilly, Novo Nordisk, and Roche Diagnostics; the sponsors had no input into the study protocols. LVG (Luc van Gaal) declares that he has no competing interests. ES (Eberhard Standl) reported personal fees from Oxford Diabetes Trials Unit, Bayer, Berlin Chemie, Boehringer Ingelheim, Merck, Novartis, and Novo Nordisk.

References

1. FDA. Guidance for industry diabetes mellitus—evaluating cardiovascular risk in new antidiabetic therapies to treat type 2 diabetes—guidance document. 2008.
1. (FDA) USFaDA. Type 2 diabetes mellitus: evaluating the safety of new drugs for improving glycemic control guidance for industry (Draft) 2020 [Available from: https://www.fda.gov/regulatory-information/search-fda-guidance-documents....
1. (NCD-RisC) NRFC. Worldwide trends in diabetes prevalence and treatment from 1990 to 2022: a pooled analysis of 1108 population-representative studies with 141 million participants. Lancet 2024; 404(10467): 2077–93. - PMC - PubMed
1. Federation WO. Prevalence of obesity 2024 [Available from: https://www.worldobesity.org/about/about-obesity/prevalence-of-obesity.
1. Blüher M, Ceriello A, Davies M, Rodbard H, Sattar N, Schnell O, et al. Managing weight and glycaemic targets in people with type 2 diabetes-how far have we come? Endocrinol Diabetes Metab. 2022;5(3): e00330. - PMC - PubMed

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- BioMed Central
- PubMed Central
Medical
- MedlinePlus Health Information
Research Materials
- NCI CPTC Antibody Characterization Program
Miscellaneous
- NCI CPTAC Assay Portal

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

CVOT summit report 2024: new cardiovascular, kidney, and metabolic outcomes

Affiliations

CVOT summit report 2024: new cardiovascular, kidney, and metabolic outcomes

Authors

Affiliations

Abstract

Conflict of interest statement

References

MeSH terms

LinkOut - more resources

Full Text Sources

Medical

Research Materials

Miscellaneous